Legend Biotech (LEGN) Director Peter Salovey Receives 28,330 RSU Award

What Happened
Peter Salovey, a director of Legend Biotech Corp (LEGN), was granted 28,330 restricted stock units (RSUs) on 2026-09-24. The RSUs were awarded with a $0.00 purchase price (standard for equity compensation); they represent contingent rights to receive ordinary shares upon settlement rather than an immediate cash purchase. If settled in ordinary shares, the award equals 28,330 ordinary shares (equivalent to 14,165 ADSs, since each ADS = 2 ordinary shares).

Key Details

• Transaction date: 2026-09-24; Form 4 filed: 2026-09-28 (filed within the usual two-business-day window).
• Security/amount: 28,330 RSUs (award, Code A); reported acquisition price $0.00.
• Vesting: 1/3 of the RSUs vest on December 20, 2027; remaining 2/3 vest in 12 equal quarterly installments beginning March 20, 2028, subject to continued service.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: ADS structure noted — each ADS represents two ordinary shares; each RSU converts to one ordinary share upon settlement.
• Nature of transaction: Compensation award (not an open-market purchase or sale); grants are routine director compensation and do not by themselves indicate buying/selling sentiment.

Context
RSU grants are a common form of director/executive compensation and vest over time to align interests with shareholders; they do not result in immediate share ownership until settlement/vesting. Because this is an award (not a purchase or sale), it’s descriptive of compensation rather than a direct market signal.